Winter begonia

Other Names

AlepgayaAshmabhedAshmabhedaAshmabhidAsmaribhedaBatpiaBegonia evansianaBegonia grandisBegonia grandis subsp. evansianaBegonia × hiemalisBergenia ciliataBergenia ligulataBergenia pacumbisDakachruDharposhElatior begoniaHardy begoniaHimasagaraHittagaHittulakaKachaluKallorvanchiKallurvanchiKallurvanniKhamdamdawiKnesebeckia discolorKondapindiMegasea ciliataNagabhidNagbhitaPaashanbhedaPahanbhediPakhanabhedPakhanabhedaPakhanbhedaPandamdawiParwatbhedPasanberuPasanbhediPashanaPashanabhedaPashanbhedPashanbhedaPatharchuriPatharkuchiPatrankurRieger begoniaSaxifraga ciliataSaxifraga ligulataSaxifraga thysanodesShilabhedShukaidouSilabhedaSilparoSilpbhedaSirupilaiStone breakerStone flowerTelanurupindiUpalbhedakWinter-flowering begonia

Synopsis

Winter Begonia (Bergenia ligulata / Begonia grandis): A Comprehensive Reference

Terminological Note and Scope of this Article

The common name "Winter Begonia" is applied to two botanically distinct plants in the dietary supplement and traditional medicine literature, and this dual usage is a persistent source of confusion. The first and pharmacologically better-documented plant is Bergenia ligulata (Wall.) Engl. (family Saxifragaceae), a perennial Himalayan herb historically known in South Asian medicine as Pashanbheda ("stone breaker"). The second is Begonia grandis Dryand. (family Begoniaceae), used in Traditional Chinese Medicine (TCM) and also loosely called "Winter Begonia." The two are not closely related: Bergenia ligulata is also called "stone flower" or "stone breaker" because its rhizomes have been used traditionally in herbal formulations for dissolution of kidney and bladder stones. Despite sharing a common English name, their botanical families, chemical profiles, and documented pharmacological activities differ substantially, and they should not be conflated in clinical or nutritional contexts. This article covers both plants together, clearly noting which findings apply to which species throughout.

1. Identity, Botanical Classification, and Natural Sources

1.1 Bergenia ligulata (Wall.) Engl. — "Pashanbheda"

Bergenia ligulata (Wall.) Engl. is commonly known as "Pashanbheda" or "stone breaker," and is a perennial herb of the family Saxifragaceae, widely utilized in South Asian traditional medicine for the prevention and treatment of urinary and renal disorders.

Bergenia (Saxifragaceae) genus is native to central Asia and encompasses 32 known species, of which nine are of pharmacological relevance. B. ligulata is distributed in the Indian sub-continent along the high-altitude Himalayan regions ranging from Kashmir to Bhutan, including West Bengal and the northeastern states. It is a perennial herb mostly found in Pakistan as well as Central and East Asia in temperate regions of the Himalayas, from Kashmir to Bhutan and in Khasia hills at 1,500 m altitude.

The plant has simple leaves of orbicular to obovate shape, a stout root stock, and solid barrel-shaped cylindrical rhizome (1.5–3 cm in length and 1–2 cm in diameter). The rhizome is the primary part used in medicine and dietary supplements.

A taxonomic note of importance: Bergenia pacumbis (Buch.-Ham. ex D.Don) C.Y.Wu & J.T.Pan (synonym: Bergenia ligulata Engl.) is an important medicinal plant belonging to the Saxifragaceae family, not to be confused with Bergenia ciliata (Haw.) Sternb., and is popularly known as Pashanbheda (meaning to dissolve the kidney stone).

1.2 Begonia grandis Dryand. — "Winter Begonia" (TCM)

Begonia grandis Dryand. (Family: Begoniaceae) has been screened for its phytoconstituents and evaluated for its ethnomedicinal potential as an antioxidant and hepatoprotective agent. The leaves of Begonia grandis Dryand. subsp. grandis represent the northernmost and most cold-resistant representative of the predominantly tropical genus Begonia.

The genus Begonia L. (Begoniaceae), comprising about 2,151 species, is widely used in traditional medicine across various regions, particularly in India and Nepal, where numerous species have been employed to treat a broad range of ailments, underscoring their ethnomedicinal significance.

1.3 Common Preparations and Forms

For Bergenia ligulata, the rhizome is the principal commercial and therapeutic preparation. Common forms encountered in trade and research include:

Dried rhizome powder (used for decoctions)
Aqueous, methanolic, and ethanolic extracts (used in laboratory studies)
Standardized multi-herb formulations: The rhizome of Bergenia ligulata is one of the major ingredients of Cystone® (Himalaya) and Calcury (Charak Pharma), two herbal formulations commonly used for treating kidney stones.

For Begonia grandis, preparations include whole-plant decoctions and leaf/stem extracts, primarily within TCM multi-herb formulae. Begonia species are rich in vitamin C and polyphenols, and various species are utilized both as food and medicine in numerous countries; the leaves have a distinctive flavor and are traditionally cooked with fish and meat, consumed raw as medicinal salads, or prepared in soups.

2. Traditional and Historical Uses

2.1 South Asian Traditions (Ayurveda, Unani, Siddha) — Bergenia ligulata

The plant has been used as a folk medicine since ancient times for dissolving kidney stones and is referred to as "Paashanbheda" (Sanskrit: Paashan meaning "rockstone" and bheda meaning "piercing") in the Indian traditional system of medicine — Ayurveda.

In the Indian system of traditional medicine (Ayurveda), "Pashanabheda" (stone breaker) is an elite drug formulation obtained from the rhizomes of B. ligulata. The plant features in classical Ayurvedic and related South Asian formularies alongside Unani and Siddha traditions. Himalayan communities consume the roots and rhizomes of the plant to treat wounds, septic, cough and cold, cardiac diseases, asthma, inflammation, gastrointestinal disorders, and different kinds of urinary problems.

Bergenia ligulata is one such perennial herb commonly used in South Asia and has been shown to possess antidiabetic, diuretic, astringent, cardiotonic, wound healing, antipyretic and anti-hemorrhoidal activities. It grows against rocks and is popularly known as Pashanbheda (dissolve the stone), signifying its use in herbal formulations for urolithiasis.

2.2 Traditional Chinese Medicine — Begonia grandis

Begonia grandis, known in Traditional Chinese Medicine (TCM) as Yu Zhu or Di Huang Hua, has been traditionally used for a variety of ailments, including inflammation, coughs, and detoxification. There are records in some Chinese herbal compendia and folk medicine sources that suggest its use as an adjunctive treatment for tumors or cancer, often in combination with other herbs; the rationale in TCM is generally based on its supposed properties of "clearing heat and toxins" and "dissipating stasis," which are metaphorically linked to tumor growth in TCM theory.

In Chinese traditional herbal practice, a decoction is used in the treatment of traumatic pain, haematemesis, gonorrhoea, post-partum vaginal discharge, amenorrhoea, and snakebites. These broad indications reflect the general role of Begonia grandis in balancing what TCM practitioners characterize as heat and blood stasis conditions.

2.3 Nepal, Himalayan, and Northeast Indian Folk Uses

A 2025 systematic review found that 41 Begonia species are used to treat a wide array of ailments, including those related to the respiratory system, skin, digestive system, and others. In Nepal specifically, leaves of Begonia have been used to treat wounds, toothaches, and fevers.

In Chinese provincial folk medicine, Bergenia purpurascens (a related species) also demonstrates the broader tradition surrounding this genus: in China, bergenin has been made into antitussive and expectorant agents; in Sichuan and Guizhou provinces, B. purpurascens is used to treat cough; it is used to treat vomiting, dizziness and cough in Xinjiang; and can treat dysentery and diarrhea in Tibet and bronchitis in Xinjiang and Yunnan.

3. Key Chemical Constituents and Mechanisms of Action

3.1 Bergenia ligulata — Primary Phytochemicals

The phytochemical profile of B. ligulata is dominated by bergenin — a C-glycoside of 4-O-methyl gallic acid — alongside arbutin, gallic acid, catechin, protocatechuic acid, and diverse terpenoids and flavonoids, collectively contributing to its bioactivity.

Other important phytochemicals in B. ligulata include afzelechin, β-sitosterol, catechin, leucocyanidin, gallic acid, and tannic acid. These substances have a number of significant biological activities including anti-bacterial, anti-inflammatory, and free-radical-scavenging properties.

Phytochemical studies have shown the presence of many secondary metabolites belonging to coumarins, flavonoids, benzenoids, lactone, carbohydrate, tannins, phenols, and sterols.

Phytochemical investigation across nine Bergenia species, including B. ligulata, led to the characterization of 152 chemical compounds (47 volatile, 105 non-volatile), categorized into polyphenols, flavonoids, quinones, sterols, terpenes, tannins, lactones, and others. Major bioactive compounds identified include bergenin, (+)-catechin, gallic acid, β-sitosterol, catechin-7-O-β-d-glucoside, (+)-afzelechin, arbutin, 4-O-galloylbergenin, 11-O-galloylbergenin, caffeoylquinic acid, and pashaanolactone.

3.2 Bergenin: The Signature Compound

Bergenin is a glycosidic derivative of trihydroxybenzoic acid that was discovered in 1880 by Garreau and Machelart from the rhizomes of Bergenia crassifolia (Saxifragaceae), and since its first report has aroused interest because of several pharmacological activities, mainly antioxidant and anti-inflammatory.

In addition to antioxidant and anti-inflammatory effects, bergenin has shown potential antimalarial, antileishmanial, trypanocidal, antiviral, antibacterial, antifungal, antinociceptive, antiarthritic, antiulcerogenic, antidiabetic/antiobesity, antiarrhythmic, anticancer, hepatoprotective, neuroprotective, and cardioprotective activities.

The medicinal properties of B. ligulata have been primarily attributed to bergenin, its most potent bioactive component. Activity-guided fractionation led to the isolation of the most potent antilithiatic metabolite from the rhizome of Bergenia ligulata; spectroscopic analysis revealed it as bergenin, which showed reducing ability and H₂O₂ scavenging activity comparable with the commercially available antioxidant, α-tocopherol.

3.3 Begonia grandis — Phytochemical Profile

Preliminary phytochemical studies of B. grandis revealed the presence of alkaloids, flavonoids, glycosides, triterpenoids, and steroids. In glandular and non-glandular trichomes as well as in epidermal cells of B. grandis leaves, phenolic compounds including flavonoids, as well as terpenoids and carbonyl compounds were detected. The patterns of phenolic compounds in acetone and ethanol leaf exudates contained oxalic, citric, and gallic acids, isoquercitrin, and orientin.

The extract of Begonia grandis decreased hepatotoxic activity due to the presence of phytochemical compounds such as glycosides, alkaloids, steroids, triterpenoids, and flavonoids. Diversity of secondary metabolites of B. grandis is the basis of its antioxidant, antimicrobial, and anti-inflammatory effects.

Across the genus, a total of 56 compounds have been identified from 13 species.

3.4 Mechanisms of Action

The anti-urolithiatic mechanism for Bergenia ligulata is the most rigorously described. These effects are mediated through inhibition of calcium oxalate crystallization, modulation of oxidative stress and inflammatory pathways (NF-κB, MAPK), enhancement of diuresis, and preservation of renal tissue integrity.

For the antioxidant mechanism: at a dose of 10 mg/kg body weight in treated rats, bergenin protected against deleterious effects of lithogenic treatment including weight loss, impaired renal function, and oxidative stress, manifested as increased malondialdehyde, reduced redox ratio, and decreased antioxidant enzyme activities in hyperoxaluric rat kidneys. The creatinine clearance and kidney damage were more improved by bergenin than by crude extract, and its antilithiatic activity was attributed to its antioxidant capability.

At the cellular level, oxalate-injured HK2 cells co-treated with ethanolic extract of Bergenia ligulata displayed increased viability, reduced oxidative stress due to lowered production of intracellular reactive oxygen species (ROS), and decreased apoptosis.

A recent study revealed that ethanolic extract of B. ligulata rhizome exerts cytoprotective effects against oxalate-mediated renal injury by downregulation of mitogen-activated protein kinases (MAPK), osteopontin (OPN), nuclear factor kappa B (NF-κB), and caspase-3, and reduction of nucleation, aggregation, and modulation of crystal structure.

4. Scientific Evidence by Area of Use

4.1 Urolithiasis (Kidney Stone Prevention and Dissolution) — Bergenia ligulata

This is the most extensively investigated area for B. ligulata.

The anti-urolithiatic potential of Bergenia ligulata represents its most extensively investigated pharmacological domain, reflecting its long-standing ethnomedicinal use in the management of renal calculi and urinary disorders.

In vitro evidence: The crude aqueous-methanolic extract of Bergenia ligulata rhizome (BLR) inhibited calcium oxalate crystal aggregation and crystal formation in metastable solutions, and exhibited antioxidant effect against DPPH free radical and lipid peroxidation in vitro. The calcium oxalate crystallization inhibition efficacy of aqueous root extract of Bergenia ligulata (BLAE) was investigated through in vitro experimental procedures — nucleation and aggregation assays — and BLAE showed dose-dependent inhibition, with more percentage inhibition of calcium oxalate crystallization observed with increasing concentration.

Animal (in vivo) evidence: An in vivo study on Wistar rats revealed the antilithiatic potential of the crude aqueous-methanolic extract when treated for 21 days at a dose of 5–10 mg/kg body weight, significantly inhibiting calcium oxalate aggregation in the renal ducts. BLR caused diuresis in rats accompanied by a saluretic effect. In an animal model of urolithiasis developed in male Wistar rats by adding 0.75% ethylene glycol in drinking water, BLR (5–10 mg/kg) prevented CaC₂O₄ crystal deposition in the renal tubules; the lithogenic treatment caused polyuria, weight loss, impairment of renal function, and oxidative stress, which were prevented by BLR.

In a bioactivity-guided fractionation study, ethylene glycol in drinking water (0.75% v/v) for 28 days was used to induce urolithiasis, and treatment with mother extract and DCM fraction at doses of 185 mg/kg and 7 mg/kg, respectively, resulted in a significant decrease in serum and urine markers of stone disease. A lower dose (0.5 mg/kg) of the EtOH extract of B. ligulata rhizome also encourages diuresis in rats and is effective in dissolving preformed stones.

Clinical/human evidence: Its efficacious nature has led to its incorporation in various commercial herbal formulations such as Cystone and Neeri, which are prescribed for kidney-related ailments. A meta-analysis of 50 clinical studies of the Cystone formulation (which contains Bergenia ligulata/ciliata as a key ingredient) concluded: Cystone® is more effective than a placebo in the treatment of urinary tract stones, significantly inducing stone size decrement and clearance compared to placebo; however, the low quality of reports is a major limitation in the applicability of these results. No published controlled clinical trial isolating B. ligulata alone, separate from a multi-herb formulation, has been identified in the available peer-reviewed literature.

Strength of evidence: Preclinical evidence (in vitro and animal models) is substantial and mechanistically coherent. Preclinical evidence strongly supports its traditional use in urolithiasis, though well-designed clinical trials remain scarce.

4.2 Antioxidant Activity

Oxidative stress is a key contributor to renal injury, inflammation, and urolithiasis, and the antioxidant potential of Bergenia ligulata has been widely examined in both in vitro and in vivo models.

The antioxidant effect of the methanolic extract of B. grandis was assessed by DPPH, superoxide, and hydroxyl radical scavenging activity; the extract showed significant antioxidant effects at a dose of 400 mg/kg comparable to those observed with ascorbic acid and silymarin.

In an in vitro study of six medicinal plants from western Nepal, the highest antioxidant activities were observed in Bergenia pacumbis (a close relative/synonym) against both DPPH (IC₅₀ = 25.97 ± 0.19 μg/mL) and ABTS (IC₅₀ = 14.49 ± 0.40 μg/mL).

Strength of evidence: Antioxidant activity has been robustly demonstrated in vitro and in rodent models for both B. ligulata and B. grandis. No human clinical trials specifically addressing antioxidant outcomes have been identified.

4.3 Anti-inflammatory Activity

Significant anti-inflammatory and anti-bacterial activities have been reported after oral administration of 50% ethanolic extract of B. ligulata in male Wistar rats at a dose of 1 g/kg body weight.

Bergenia species possess several biological activities including anti-inflammatory, among others. At the mechanistic level, the anti-inflammatory effects are linked to modulation of the NF-κB pathway and reduction of inflammatory markers.

For Begonia grandis, Winter Begonia (Begonia grandis) has been traditionally used for a variety of ailments including inflammation, coughs, and detoxification.

Strength of evidence: Preclinical (in vitro and rodent models) only. No well-controlled human trials were identified.

4.4 Hepatoprotective (Liver-Protective) Activity

Studies have demonstrated that extracts from Begonia species can prevent liver damage and reduce inflammation in rat models, indicating that their antioxidant content is linked to their hepatoprotective qualities. A study correlated the antioxidant property of phytochemicals present in the root extract of Begonia grandis against CCl₄-induced hepatotoxicity in rats, with the result showing that the cellular structure of the rat liver was intact at the higher dose of 400 mg/kg, demonstrating a considerable decrease in inflammatory and necrotic alterations. Phytochemical studies of the root extract revealed the presence of alkaloids, glycosides, flavonoids, steroids, and triterpenoids, which were attributed to the hepatoprotective activity, thereby justifying the traditional use of B. grandis in the treatment of liver disorders.

Strength of evidence: Animal studies only. No human trials identified.

4.5 Antipyretic Activity

Oral administration of B. ligulata extract at a dose of 500 mg/kg body weight in Wistar rats showed strong antipyretic activity against yeast-induced fever.

Strength of evidence: Preclinical (rodent model) only. No human trials identified.

4.6 Antimicrobial Activity

Antimicrobial effects of the aqueous ethanol extract and of the ethanol exudate of Begonia grandis against reference strains of Bacillus subtilis, Staphylococcus aureus, and Candida albicans were detected at disc contents of 50.0 and 45.8 μg, respectively.

It has been demonstrated that compounds found in Begonia species, such as terpenoids, flavonoids, and alkaloids, hinder the growth of several bacteria and fungi. Research has revealed that the ethanolic extract of Begonia multangula leaves can inhibit the biofilm formation of Candida albicans, suggesting the antimicrobial potential of these species as a practical and natural alternative for treating bacterial infections and addressing antibiotic resistance. Begonia grandis leaves have also been demonstrated to have strong antimicrobial effects in aqueous preparations.

Methanolic extract of B. ligulata rhizomes exhibited inhibitory activity against viral RNA and peptide synthesis.

Strength of evidence: In vitro evidence only. No human clinical trials on antimicrobial endpoints were identified for either species.

4.7 Antidiabetic Activity

Bergenia species have been documented as possessing antidiabetic activity among other biological activities. Bergenia ligulata is an important medicinal plant used in traditional systems of medicine for its diuretic, antilithiatic, antidiabetic, antibacterial, and anticancer properties.

Modern pharmacology has shown that bergenin's pharmacological effects include antibacterial, antiviral, cough-relieving, and anti-inflammatory actions; in addition, it could inhibit diabetic neuropathy, restore insulin secretion, treat cancer, protect the liver, and prevent Alzheimer's disease.

Strength of evidence: Predominantly in vitro and animal model evidence. Human clinical trial data are lacking.

4.8 Antileishmanial Activity

In vitro and in vivo studies on B. ligulata have shown strong protective properties against Leishmania donovani infection, the parasitic load being reduced by more than 95% at a high dose of 1000 mg/kg body weight in a mouse model.

Strength of evidence: Preliminary in vitro and animal evidence only.

4.9 Cytotoxic / Anticancer Activity

The cytotoxic properties of Begonia species have been investigated, with a focus on their effects on cancer cell lines such as HeLa and MOLT-4 to scientifically validate their use in traditional practices. An in vitro cytotoxic study of B. roxburghii leaf extracts against MOLT-4 and HeLa cell lines showed 80.66% cell death at a dose of 25 mg/mL during the MTT assay.

For Begonia grandis specifically: there is little direct scientific evidence supporting the anticancer effects of Winter Begonia. Some in vitro studies may show cytotoxic effects of extracts from Begonia species against certain cancer cell lines, but these are preliminary, not specific to clinical cancer therapy, and often use non-standardized preparations.

Applying Bergenia ligulata silver nanoparticles (BgAgNps) resulted in significant cytotoxic effects on MCF-7 breast cancer cells, decreasing cell viability and migratory capacity; BgAgNps demonstrated a notable increase in programmed cell death potentially through ROS production via oxidative stress and a decline in mitochondrial membrane potential.

While its use for cancer is rooted in tradition, and there are some early-stage laboratory findings, there is insufficient scientific validation for its use as a cancer therapy; the evidence supporting this practice is not endorsed by modern medical guidelines.

Strength of evidence: In vitro only; highly preliminary. No human clinical trial data exist for either species in this context.

5. Body Systems and Health Areas

Based on peer-reviewed literature, the following body systems and health areas are associated with these plants:

Urinary/Renal System: Anti-urolithiatic (kidney stone prevention and dissolution), diuretic, cytoprotection of renal epithelial cells — most robustly studied area for B. ligulata.
Hepatic System: Hepatoprotective effects documented in rodent models for B. grandis.
Immune/Infectious Disease: Antibacterial, antifungal, antiviral (in vitro); antileishmanial (animal models) for B. ligulata.
Inflammatory Pathways: Inhibition of NF-κB and MAPK-related inflammatory signaling.
Metabolic System: Antidiabetic / antiobesity activity (preclinical).
Respiratory System: Antitussive (cough-suppressing) use documented in traditional Chinese medicine and preliminary pharmacological data.
Cardiovascular System: Cardioprotective and cardiotonic activities cited in traditional use and preliminary studies.
Oncology (Exploratory): Cytotoxic effects on cancer cell lines (in vitro only; no clinical relevance established).

Literature investigation reveals that Begonia species are widely used in traditional medical practices against various human ailments including respiratory, digestive, and dermatological disorders, and many others.

6. Dosage Forms and Reported Doses

The following dosages are reported in the scientific literature and relate exclusively to preclinical (animal) or formulation studies. No confirmed therapeutic human dose for isolated extracts has been established in clinical trials.

Bergenia ligulata crude aqueous-methanolic extract (BLR) at 5–10 mg/kg body weight in a rat urolithiasis model prevented calcium oxalate crystal deposition in renal tubules.
Oral administration of the extract at a dose of 500 mg/kg body weight in Wistar rats showed strong antipyretic activity against yeast-induced fever.
Significant anti-inflammatory and anti-bacterial activities have been reported after oral administration of 50% ethanolic extract of B. ligulata in male Wistar rats at a dose of 1 g/kg body weight.
At a dose of 10 mg/kg body weight, bergenin (isolated compound) protected against deleterious effects of lithogenic treatment in hyperoxaluric rats.
The methanolic extract of B. grandis showed significant antioxidant and hepatoprotective effects at a dose of 400 mg/kg in a rodent model.
In a fractionation study, mother extract and DCM fraction at doses of 185 mg/kg and 7 mg/kg, respectively, in ethylene glycol-induced rats resulted in a significant decrease in serum and urine stone markers.
A lower dose (0.5 mg/kg) of the EtOH extract of B. ligulata rhizome encourages diuresis in rats and is effective in dissolving preformed stones.
Antileishmanial activity was observed at a high dose of 1000 mg/kg body weight in a mouse model.

7. Safety Considerations and Interactions

7.1 Acute Toxicity Data

In a study, it was confirmed that ethanolic extract of Bergenia rubrovenia root was safe up to a dose level of 2000 mg/kg, as the rats under examination did not exhibit any aberrant behavioral or neurological signs following the acute oral toxicity protocol. Likewise, the acute toxicity of the methanol root extract of Begonia grandis in female albino rats was also tested, where no abnormality or mortality was observed up to the dose level of 2000 mg/kg.

7.2 Oxalic Acid Content

The phenolic compounds in Begonia grandis leaves include oxalic, citric, and gallic acids among others. The presence of oxalic acid in Begonia grandis leaf preparations is a relevant consideration, since dietary oxalate can contribute to urinary oxalate load and potentially promote calcium oxalate stone formation in susceptible individuals — a notable irony given that a related plant (Bergenia ligulata) is used to prevent such stones.

7.3 Heavy Metals and Contaminant Considerations

Heavy metal analysis in Begonia palmata leaves indicated that arsenic, cadmium, copper, lead, mercury, antimony, and tin were within permissible limits, while chromium and nickel exceeded permissible limits. This finding from a closely related Begonia species underscores the importance of quality control and sourcing verification for commercial preparations from wild-harvested Himalayan/South Asian begonias.

7.4 Evidence Gaps and Research Limitations

Despite extensive traditional use, comprehensive scientific documentation on the ethnomedicinal applications, phytochemical profiles, and pharmacological properties of Begonia species remains limited. Existing studies are often fragmented, and the evidence supporting traditional claims is frequently inconsistent or preliminary.

Standardization of extracts, toxicological validation, and translational clinical studies are essential to advance its integration into evidence-based primary care and herbal pharmacotherapy.

Although different plant extracts of Begonia species have been studied for a wide range of pharmacological activities through both in vitro and in vivo experiments, there is meager information available on their toxicity and side effects.

7.5 Species Misidentification

A documented safety-related concern is species misidentification. The name "Pashanbheda" has historically been applied to multiple species within the genus Bergenia (including B. ligulata, B. ciliata, B. stracheyi, and others), and commercial preparations may not reliably differentiate between them. Botanical authentication of the raw material is therefore an important quality standard for any product based on this ingredient.

References

Health Conditions

Health conditions that Winter begonia may help support.

No conditions available.

Body Systems

Body systems that Winter begonia may help support.

No body systems available.